Otra hiptesis relevante seala que los cambios metablicos bruscos, como la rpida prdida de peso o la mejora sbita del control glucmico, podran generar un estrs adicional sobre el nervio ptico
The US Food and Drug Administration (FDA) approved the Wegovy (semaglutide) injection for reducing the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease who are obese or overweight
While originally developed for blood sugar management, GLP-1 and GIP therapies are now commonly used under medical supervision to support metabolic health, weight management, and body composition in individuals who meet appropriate criteria
The majority of the participants were prescribed to a regimen involving 7.2 mg weekly doses of semaglutide medication, triple the standard dose
Semaglutide works similarly to GLP-1 to: Reduce your desire for food Slows down the speed at which food moves out of your stomach This will decrease your appetite and help you reach your weight loss goals
According to a study in The New England Journal of Medicine (source), Semaglutide helps the body regulate blood sugar and can slow the digestion process